Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC1779 in von Willebrand disease type 2B
2008-008532-82Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Jan 2009
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of egaptivon pegol in von Willebrand disease type 2B (VWD2B), sponsored by Medical University of Vienna. Primary endpoint: Platelet count. Started Jan 2009; status: completed.
02
Drugs
egaptivon pegol
03
Conditions
von Willebrand disease type 2B (VWD2B)
Beyond the preview
Go deeper on 2008-008532-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008532-82.